Isoniazid therapy in Parkinson's disease
Isoniazid therapy in Parkinson's disease
复制标题
异烟肼治疗帕金森病
DOI：
10.1002/mds.870030205
复制
发表时间：
1988
影响因子：
8.6
通讯作者：
tJ. A. Obeso
中科院分区：
文献类型：
--
作者：
tM. R “0. S . Gershanik;Luquin;O. Scipioni;tJ. A. Obeso
在20例帕金森病患者中评价了异烟肼对左旋多巴诱导的运动障碍的影响，此前偶然观察到1例帕金森病患者在异烟肼治疗结核感染期间左旋多巴诱导的舞蹈性运动障碍明显减少。异烟肼的平均剂量为290 mg，目前的抗帕金森病治疗没有任何变化。在治疗的最初几周内，18名患者的“剂量获益”舞蹈性运动障碍明显减少。这种影响伴随着无法忍受的帕金森症状恶化。在异烟肼干扰左旋多巴和多巴胺激动剂的治疗作用后，所有患者均恢复至基础状态。这种作用发生的确切机制尚不清楚，但讨论了几种可能的解释。
The effect of isoniazid on levodopa‐induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. “Benefit of dose” choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.